Long-term human safety profile requires further validation
N Engl J Med 389(24):22212232 Urva S, Coskun T, Loh MT et al (2022) LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
Over the past 20 years, a few dozen preclinical studies (meaning research conducted in animals or cells and not in human trials) have yielded potentially promising data suggesting that the peptide can fight inflammation and promote protein synthesis and angiogenesis (the fancy scientific term for the process by which your body produces new blood vessels)
[1] [3] Zepbound carries a Boxed Warning about thyroid C-cell tumors that have occurred in rodent studies